Epigral Limited Reports 25% PAT Growth in Q1 FY27, Approves ₹600 Crore Expansion into Epoxy Resins
Integrated chemical manufacturer posts strong quarterly earnings and announces major capacity expansion to strengthen specialty chemicals portfolio
Epigral Limited (NSE: EPIGRAL | BSE: 543332) has announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27), reporting strong growth in revenue and profitability despite a challenging global operating environment.
The company posted a 25% year-on-year (YoY) increase in Profit After Tax (PAT) to ₹99 crore, while revenue from operations rose 15% YoY to ₹709 crore, supported by healthy volume growth, improved realizations, and stable plant utilization.
Q1 FY27 Financial Highlights
Epigral delivered healthy growth across its key financial metrics during the quarter.
- Revenue from Operations: ₹709 crore, up 15% YoY from ₹615 crore.
- EBITDA: ₹179 crore, registering 10% YoY growth.
- EBITDA Margin: 25%.
- Profit After Tax (PAT): ₹99 crore, compared with ₹79 crore in Q1 FY26, reflecting 25% YoY growth.
- Sales Volume: Increased 5% YoY.
- Plant Utilization: Remained above 80% across manufacturing facilities.
The company’s performance was driven by higher volumes, better pricing, and continued operational efficiencies despite ongoing global macroeconomic uncertainties.
Board Approves ₹600 Crore Growth Capex
To support its long-term growth strategy, Epigral’s Board of Directors has approved an investment of approximately ₹600 crore for the establishment of:
- An Epoxy Resin and Formulations manufacturing facility
- A new Multi-Purpose Plant (MPP)
The expansion represents the company’s entry into the epoxy resin business, further diversifying its specialty chemicals portfolio.
New Epoxy Resin Plant to Target High-Growth Industries
The proposed epoxy resin facility will have an annual production capacity of 125,000 tonnes per annum (TPA).
The products will cater to rapidly growing industries, including:
- Renewable energy, particularly wind turbine blades
- Construction and infrastructure
- Automotive
- Electronics
- Aerospace
The Multi-Purpose Plant will manufacture downstream products in the Epichlorohydrin (ECH) and Chlorotoluenes value chains, serving sectors such as pharmaceuticals, agrochemicals, and water treatment chemicals.
Integrated Manufacturing to Provide Cost Advantage
Epigral stated that the new projects will leverage its existing integrated manufacturing complex, providing significant operational and cost efficiencies.
More than 50% of the key raw material requirements, including Epichlorohydrin (ECH) and Caustic Soda, will be supplied through the company’s existing facilities, strengthening backward integration and improving overall competitiveness.
Commercial Operations Expected in H2 FY28
The company expects both the Epoxy Resin plant and the Multi-Purpose Plant to commence commercial production during the second half of FY28.
A pilot production facility is expected to become operational by Q2 FY27, enabling product validation and customer qualification ahead of commercial-scale production.